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Molecular Diagnostics
Accreditation, setting and experience as indicators to assure
quality in oncology biomarker testing laboratories
Véronique Tack1, Ed Schuuring2, Cleo Keppens1, Nils ‘t Hart2, Patrick Pauwels3, Han van Krieken4 and Elisabeth M.C. Dequeker1
BACKGROUND: Predictive biomarkers allow clinicians to optimise cancer treatment decisions. Therefore, molecular biomarker test
results need to be accurate and swiftly available. To ensure quality of oncology biomarker testing, external quality assessments
(EQA) for somatic variant analyses were organised. This study hypothesised whether laboratory characteristics inﬂuence the
performance of laboratories and whether these can be imposed before authorisation of biomarker testing.
METHODS: Longitudinal EQA data from the European Society of Pathology were available over six (metastatic colorectal cancer)
and four years (non-small cell lung cancer), including the percentage of analysis errors and technical failures, and information on
laboratory characteristics (accreditation status, laboratory setting, number of samples analysed and detection method). Statistical
models for repeated measurements were used to analyse the association between the EQA results and the laboratory
characteristics.
RESULTS: Laboratory accreditation was associated with fewer analysis errors in early stages of biomarker introduction into the
laboratory. Analysing more samples, or university and research laboratories showed better performance. Changing the detection
method did not have an effect.
CONCLUSION: The indicators support the clinicians in choosing molecular pathology laboratories by improving quality assurance
and guaranteeing patient safety. Accreditation of laboratories, centralisation of biomarker testing or a university and research
setting should be stimulated.
British Journal of Cancer (2018) 119:605–614; https://doi.org/10.1038/s41416-018-0204-9
INTRODUCTION
Pathology laboratories are challenged to maintain high quality
assurance due to the constant pressure of newly developed
technical and medical expertise. Research on predictive biomar-
kers has gained considerable momentum, highlighting the need
for regular updates of test strategies.1,2
Predictive biomarkers allow clinicians to predict clinical effects
of cancer treatments.3 For this purpose, biomarker test results
need to be very accurate and swiftly available. For metastatic
colorectal cancer (mCRC), the conﬁrmation of a wild-type KRAS
and NRAS gene is required before anti-EGFR monoclonal antibody
therapies.4–7 In the context of non-small-cell lung cancer (NSCLC),
treatment with EGFR tyrosine kinase inhibitors requires the
presence of an activating variant in the EGFR gene. Moreover,
ALK and ROS1 gene tyrosine kinase inhibitor (TKI) treatment can
only be administered to patients with a conﬁrmed gene
rearrangement in the mentioned genes.8–11 Recently, the immune
checkpoint inhibitor, pembrolizumab, was approved by the US
Food and Drug Administration (FDA) in ﬁrst line therapy for
patients with ≥50% positive PD-L1 expression in NSCLC, as
assessed by immunohistochemistry (IHC).12 The immune
checkpoint inhibitor nivolumab can be given to patients with
NSCLC without conﬁrmation of PD-L1 positivity.
To ensure quality of oncology biomarker testing, external
quality assessments (EQA) are organised by the European Society
of Pathology (ESP) according to international standards.13
Remarkably, each year a signiﬁcant number of laboratories are
not able to correctly identify the relevant variants.14,15
Previous research by our group in 2014 demonstrated that
laboratories were not able to rapidly introduce new accurate
biomarker testing for the use of cetuximab and panitumumab,
two anti-EGFR therapies for patients with mCRC.14 On the other
hand, multiple participations in EQA programs showed improved
performance rates.15,16 However, the number of genotyping errors
remains high.14,15 Laboratories are also challenged by the large
variation in mutation types, for example targeted variants in the
EGFR gene include point mutations, insertions and deletions,
which evolve over time.17 With the large number of ongoing
phase-III clinical trials, and the rapid developments in biomarker
testing, several new testing strategies and relevant biomarkers are
expected to be implemented each year.1,18 The insufﬁcient
performance of laboratories in EQA together with the increasing
number of biomarker tests are subjects of concern. Laboratories
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should be stimulated to maintain a high degree of quality
assurance by means of continuous education and development of
expertise in oncology biomarkers. Several longitudinal studies
were already performed on data from EQA in oncology biomarker
testing, but the inﬂuence of speciﬁc laboratory characteristics on
the performance of oncology biomarker testing has, to date, not
yet been analysed.19
Laboratory characteristics, such as accreditation, experience and
laboratory setting or organisational structure, are recognised as
important elements that could inﬂuence the performance of
laboratories.20–22 How can the hypothesis be justiﬁed that
accreditation or a minimal level of experience can be imposed
before authorisation of biomarker testing?
The aim of this study was to correlate laboratory characteristics
with EQA results in biomarker testing for NSCLC and mCRC in
order to identify important quality indicators.
MATERIALS AND METHODS
The EQA schemes of the ESP were coordinated by the Biomedical
Quality Assurance (BQA) Research Unit of the KU Leuven
according to international guidelines.13,23 The schemes were open
to all laboratories worldwide (Table 1). The participants had to
report their results in an online datasheet, together with questions
on laboratory characteristics and testing strategies. It was
mentioned in this datasheet that data could be used for further
research. In addition, mock diagnostic reports were requested
based on the information provided by the BQA Unit of the KU
Leuven. Medical and technical experts assessed the data provided
by the participants in collaboration with the EQA coordination
centre. A laboratory received full marks (2 points) when the
genotype of the requested biomarker was correctly assigned;
points were deducted in case of clerical errors, technical failures,
analysis errors or nomenclature errors. Each sample result was
evaluated by two assessors independently, and equivocal results
were discussed during a meeting. Samples for which more than
25% of the laboratories could not obtain a reliable result were not
considered for the analyses.24 These were deﬁned as educational
samples.
The EQA schemes of the ESP can be categorised into two
groups: those for variant analysis (RAS genes, including KRAS and
NRAS, in mCRC and the EGFR gene in NSCLC) and those for gene
rearrangement and expression analyses (ALK and ROS1 rearrange-
ments in NSCLC).
For variant analyses, participants should use their routine
procedures to analyse the EQA samples. The sent samples were
formalin-ﬁxed parafﬁn-embedded (FFPE) material from the resec-
tion specimens, commercial FFPE reference standards (Horizon
Diagnostics, Cambridge, U.K., http://www.horizondx.com and
Thermo Fisher Scientiﬁc; Fremont, California, www.
thermoscientiﬁc.com/qc) or cell line material.19 The cell line
material was chosen as a pilot for standardisation of homo-
geneous samples for testing. The percentages of neoplastic cells
varied between 10 and 100%.
For gene rearrangement and expression analyses, both IHC and
ﬂuorescent in situ hybridisation (FISH) techniques were included
in the EQA schemes. The samples included FFPE cell lines on glass
slides as well as tissue microarrays from several FFPE blocks from
either the cell line material or the resection specimen.19
The association study included the EQA results as the
dependent variable and the laboratory characteristic as the
independent variable (Table 2). For the EQA results, the total
EQA scores were taken into account, but also, the isolated
percentage of analysis errors or the number of technical failures
were considered. Other speciﬁc error types were not analysed
individually, but remain integrated in the EQA scores. Analysis
errors consisted of false positive (reported a variant, rearrange-
ment or aberrant expression in a wild-type sample), false negative
(wildtype was reported in a tumour containing a variant,
rearrangement or aberrant expression) or wrongly reported
variants (a variant was found, but it was an incorrect variant).
Technical failures arose when no conclusive results were reported
by the participant, either due to a limited amount of DNA
recovered from the sample or a doubtful result.
Four laboratory characteristics were used for association with
EQA results of the laboratories, namely the accreditation status of
a laboratory, their setting, the number of samples tested each year
and the change in used methods. The corresponding subcate-
gories and number of observations per characteristic can be found
in Table 2. Each observation of a characteristic denotes the
participation of a speciﬁc laboratory in a speciﬁc EQA scheme. For
the accreditation status, different national and international
standards were considered. The ISO 15189 and the ISO
17025 standards were included as recognised international
accreditation standards.25,26 Several national accreditation stan-
dards, such as CAP 15189 (College of American Pathologists), and
some widely used national standards were also taken into account
for accreditation. Examples of the latter are the national standard
in the Netherlands (CCKL) and the standards of the Clinical
Pathology Accreditation in the United Kingdom.27–30 For good
readability, both recognised accreditation standards and their
equivalents are hereafter referred to as ‘accreditation’. No
distinction was made between accreditation standards and their
equivalents for further analysis. The reported accreditation status
was retrieved from the websites of the relevant national
accreditation body. As there is still a lot of confusion in
laboratories about accreditation status, these were veriﬁed retro-
spectively.20 In case no archived data were available, these data
were deﬁned as ‘missing data’ in Table 2. Also, the effect of the
setting of a laboratory was studied. The reported setting of the
laboratories in the EQA questionnaires was veriﬁed on the
laboratory’s website. Different categories were assigned and this
terminology will be used throughout the manuscript (Table 2).
Industry denotes those laboratories involved in the development
of diagnostic commercial kits. Private laboratories are laboratories
that are not present within a hospital's infrastructure. Hospital
laboratories included private and public hospital laboratories. The
setting deﬁned as ‘university and research’ included education
and research hospitals, university hospitals, university laboratories
and anti-cancer centres, all with a clinical demand for biomarker
testing. The number of samples tested each year and the used
methods were requested during EQA participation and were not
further validated. As not all participants provided information on
the number of samples, there are some missing data for this
characteristic too. Examples of commercial methods (excluding
commercial methods based on next-generation sequencing
(NGS)) were the Therascreen Pyro Kit (Qiagen), the RAS mutation
analysis kit (EntroGen) or the Idylla Mutation Test (Biocartis). Non-
NGS-based laboratory-developed techniques (LDT) included
Sanger sequencing or TaqMan allelic discrimination assays (Fig. 2).
Longitudinal data between 2010 and 2016 were analysed using
statistical models for repeated measurements. Because of the
skewed distributions of the EQA scores, a binary outcome was
used: <90% (unsuccessful participation) and ≥90% (successful
participation). In case an EQA scheme only contained nine
samples that were eligible for scoring, because of an educational
sample, ≥88.9% was also considered as a successful participation.
For binary outcomes (successful participation versus unsuccessful
participation), generalised estimating equations (GEE) were used
to account for clustering. For continuous outcomes (percentage of
analysis errors or technical failures), an unstructured residual
covariance matrix was modelled to account for clustering.
All tests were two-sided and a p-value of <0.050 was considered
signiﬁcant. Pairwise comparisons were only performed in case of
signiﬁcant results. Analyses were performed with SAS software for
Windows (version 9.4).
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RESULTS
This study investigated the hypothesis that whether laboratories
would have to comply to speciﬁc laboratory characteristics before
the authorisation of biomarker testing. Three factors, namely, the
accreditation status of a laboratory, their setting and their
experience with oncology biomarker testing in mCRC and NSCLC
were considered. The latter included the number of samples
tested each year and the change in used methods.
Accreditation
Based on a total dataset of 691 observations (2010–2016) for
variant testing in mCRC, no association was found between the
accreditation status of laboratories and their EQA score for variant
analysis in KRAS or NRAS genes (Table 3). However, there was a
positive effect of accreditation on the percentage of analysis errors
for the NRAS biomarker (incidence rate ratio (IRR)= 0.52, p=
0.023) in the ﬁrst years of NRAS implementation in the laboratory
(2013–2014). Pairwise comparisons of different accreditation
categories in this group showed that accredited laboratories have
47% fewer analysis errors compared with laboratories without
accreditation (IRR= 0.53, p= 0.030). This signiﬁcant effect dis-
appears (p= 0.080; 2013–2016) over time, indicating that accre-
dited laboratories have a better implementation procedure
(Table 3).
The number of years that a laboratory was accredited has no
effect on the EQA result (p= 0.152) or the percentage of analysis
errors (p= 0.871) for NRAS and KRAS testing laboratories between
2012 and 2014.
For EGFR testing (2012–2016), the total number of observations
for accreditation characteristic was 453 (Table 2). An association
was found between accreditation and successful EQA scores (p=
0.018) (score ≥ 90%), and between accreditation and fewer
analysis errors (p= 0.002). The percentage of technical errors
showed no association with the accreditation status (p= 0.422)
(Table 3).
The EQA schemes for rearrangement analysis included the ALK
(2012–2015) and the ROS1 (2014–2015) biomarker (Table 1). For
rearrangement and expression analysis of ALK and ROS1 genes by
FISH or IHC, there was no effect between the EQA score or the
percentage of analysis errors and the accreditation status (Table 3).
However, accreditation is associated with less technical failures for
ALK IHC (p= 0.009) and more technical failures for ROS1 FISH (p=
0.031). Pairwise comparison of different categories showed
evidence that the coverage of ALK is not speciﬁcally required in
the scope (Table 3), however, for ROS1 FISH, ROS1-speciﬁc
accreditation is important (p= 0.017).
Figure 1 shows the statistical results of different characteristics
as an illustrative summary of the study
Setting
There is no evidence of an association between the setting of an
institute and its EQA score or percentage of analysis errors in KRAS
of NRAS testing (n= 711). For RAS analysis between 2013 and 2016
(n= 348), there is a signiﬁcant higher probability to obtain a
successful EQA score (≥90%) in the setting of university and
research versus hospitals and (private) laboratories without the
research incentive (p= 0.010 and p= 0.037, respectively). Uni-
versity and research settings were associated with less analysis
errors than hospitals and (private) laboratories, and an industry
setting showed less analysis errors compared to hospitals and
(private) laboratories (p= 0.013 and p= 0.012, respectively). In
EGFR testing, (n= 460) no association with the EQA scores was
found, however, less analysis errors were made in a university and
Table 1. Overview of the samples and number of participants included in each EQA
EQA scheme Scheme year Number of samples
distributed
Number of
participants
Number of successful
laboratories (≥90%)
Percentage analysis
errors
Percentage technical
errors
Colon (KRAS/
NRAS)
2010 10 103 598 4.3% 1.4%
2011 10 124
2012 10 105
2013 10 131
2014 10 125
2016 10 123
EGFR 2013 4 106 280 8.7% 5.0%
2014 9 144
2015 9 114
2016 10 97
ALK FISH 2012 5 54 379 3.2% 4.3%
2013 5 100
2014 8 116
2015 10 111
ALK IHC 2012 8 29 296 4.8% 1.2%
2013 12 48
2014 9 96
2015 5 95
ROS1 FISH 2014 8 56 92 2.6% 7.4%
2015 9 68
ROS1 IHC 2014 10 31 42 8.9% 0.2%
2015 5 31
Educational cases were excluded, as they were not taken into account to determine the EQA score
EQA external quality assessment
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research background, compared to (private) laboratories and
industry laboratories (p= 0.016 and p= 0.012, respectively).
For the rearrangement analyses, (n= 494, n= 368, n= 124 and
n= 61, for ALK FISH, ALK IHC, ROS1 FISH and ROS1 IHC,
respectively) (Table 2), no signiﬁcant associations were identiﬁed.
Experience with oncology biomarker testing
Table 4 shows an increasing probability to have a successful EQA
score with increasing number of samples tested per year for KRAS,
NRAS or EGFR (p= 0.002; p= 0.009; p= 0.009, respectively). Similar
results were obtained for the association with the percentage of
analysis errors, except for the number of samples tested per year
for EGFR (Table 4). In case the number of samples was considered
as an ordinal variable, we observed a decreasing number of
analysis errors with increasing category of the number of samples.
For KRAS, an IRR of 0.72 indicates a decrease of 28% of genotype
mistakes for every one-level increase, for example from <10 sam-
ples tested to 10–99 or from 10–99 to 100–249 samples tested.
With number of samples as categorical variable, the number of
analysis errors is signiﬁcantly lower in laboratories that test
10–99 samples compared with laboratories that test more than
99 samples, both for KRAS and NRAS.
For Lung ALK FISH, a higher number of samples tested per year
was associated to an improved EQA score and a decreased
percentage of analysis errors (Table 4). For an increase in level of
the samples tested per year, 32% fewer analysis errors were made
with ALK FISH analysis (IRR= 0.68, p= 0.005). This is in contrast
with results for ROS1 rearrangement testing, where no association
could be observed between the ROS1 FISH EQA scores or analysis
errors and the number of samples tested for ROS1.
For IHC tests, there was evidence of variation between EQA
scores and the categories of number of samples tested, however,
there is no conclusive evidence that the EQA score improved with
an increasing number of samples tested per year. The percentage
of analysis errors showed a difference between the number of ALK
IHC testing categories, but no conclusive results could be made
that less analysis errors were made when more samples were
tested for ALK. For ROS1 IHC, however, a 36% increase of ROS1 IHC
analysis errors was seen for every increase in the level of number
of samples tested per year.
In addition to the number of samples tested in a laboratory,
changing a routinely applied method can also inﬂuence the
experience of a laboratory with a speciﬁc biomarker. The methods
used in molecular pathology laboratories vary greatly. Figure 2
Table 2. Investigated characteristics, including the subgroups, and the number of observations for each EQA scheme
Characteristics Subcategories of the
characteristics
Colon EQA scheme
2010–2016 (all
laboratories)
Colon EQA scheme
2013–2016 (RAS
testing laboratorya)
Lung EGFR EQA
scheme
2012–2016
Lung ALK EQA
scheme
2012–2016
Lung ROS1 EQA
scheme
2014–2015
Number of observations with the characteristic
Accreditation Gene-speciﬁc
accreditation
94 23 44 59 5
Non-speciﬁc
accreditation
143 114 107 128 49
No accreditation 454 210 302 383 82
Missing data 20 1 8 17 0
Setting Industryb 22 14 16 9 3
(Private) laboratoriesc 108 63 76 55 13
Hospital laboratoriesd 238 104 121 104 25
University and
researche
343 167 248 326 83
Missing data 0 0 0 0 0
Number of samples <10 33 4 23 49 39
10–99 174 69 104 120 50
100–249 231 137 148 115 18
250–499 160 81 124 73 11
≥500 90 42 58 27 4
Missing data 23 11 4 6 2
Methods Non-NGS-based
commercial methods
/ /
Non-NGS-based
laboratory-developed
methods
See Fig. 2
NGS-based methods
Each observation is a participation of a speciﬁc laboratory in a speciﬁc EQA scheme. For the accreditation status, different national and international standards
were taken into account: ISO 15189 and ISO 17025 standards as recognised international accreditation standards,25,26 CAP 15189 (College of American
Pathologists) as national accreditation standard and widely used national standards such as the national standard in the Netherlands (CCKL) and the standards
of the Clinical Pathology Accreditation in the United Kingdom27–30
EQA external quality assessment, / information not present, NGS next-generation sequencing
aRAS testing laboratories included those laboratories that tested KRAS and NRAS genes
bLaboratories involved in the development of diagnostic commercial kits
cLaboratories that are not present within a hospital's infrastructure
dHospital laboratories included private and public hospital laboratories
eThis setting included education and research hospitals, university hospitals, university laboratories and anti-cancer centres
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gives an overview of the evolution of the distribution of different
types of methods over the years for the RAS and EGFR biomarkers.
In general, less LDTs were used over the years, while non-NGS-
based commercial methods and NGS-based techniques gained
more weight. At the time that a new predictive biomarker was
introduced in the routine, a limited number of non-NGS-based
commercial test kits was available. The implementation of a new
method for KRAS variant analysis (2010–2014) showed no
signiﬁcant association with the EQA score or the number of
analysis errors (p= 0.471, p= 0.871, respectively). As not enough
data were available on other biomarkers, no further analyses could
be performed.
DISCUSSION
The changing era of personalised medicine challenges labora-
tories to offer quality-assured biomarker testing and maintain a
high performance level for their tests. Different laboratory
characteristics are accepted as important tools for increased
quality assurance, but the question remains whether these should
be mandatory or not. This study investigated four characteristics in
laboratories testing for biomarkers in NSCLC and mCRC: accred-
itation status of a laboratory, their setting, the number of samples
tested each year and the change in used methods.
Less analysis errors were observed in accredited laboratories in
the early stages of biomarker introduction. This was demonstrated
by the positive effect for NRAS variant analysis, which is a new
biomarker introduced in laboratories in 2013, and EGFR variant
analysis.5,6 These two biomarkers (EGFR and NRAS) are essential
for therapy decision-making and will challenge the laboratories
because of the need of fast introduction in the routine or the large
spectrum of variants that needs to be tested.4,31 The inclusion of
the newly introduced biomarker in the accreditation scope is not
essential, as laboratory accreditation is intense and laborious and
stimulates the laboratory in a signiﬁcantly positive way.32
Implementation of new tests in the accredited laboratories should
follow strict standards, including the introduction of well-planned
and validated standard operating procedures. This can be seen as
a drawback of accreditation, as it could lead to postponing the
introduction of new developments. However, in the context of
biomarkers, laboratories are forced to introduce these changes, as
they become mandatory before therapy decision. In that case,
accreditation forms a welcomed basis during introduction.
Once the biomarker is successfully implemented in the
laboratory, the association between good performance and
laboratory accreditation disappears. While accredited laboratories
have addressed the difﬁculties during the extensive validation
procedure, laboratories without accreditation have gained experi-
ence during the routine execution of biomarker testing and
Table 3. Statistical results for the association between the EQA results (EQA score, analysis errors and technical failures) and the accreditation status
EQA score Analysis errors Technical failures
Odds ratio p-value IRR p-value IRR p-value
Colon EQA scheme 2010–2016 (all laboratories), n= 691
Accreditation: yes/no 1.55 0.097 0.66 0.054 1.85 0.036
KRAS accreditation (global test) NA NA NA NA NA 0.111
Colon EQA scheme 2013–2016 (RAS testing laboratories), n= 347
Accreditation: yes/no 1.56 0.151 0.62 0.080 1.67 0.147
Lung EGFR EQA scheme 2012–2016, n= 453
Accreditation: yes/no 1.72 0.018 0.55 0.002 1.22 0.422
EGFR accreditation (global test) NA 0.028 NA 0.007 NA NA
Gene-speciﬁc versus none 2.62 0.013 0.47 0.030 NA NA
Laboratory accreditation versus gene-speciﬁc 0.56 0.157 1.21 0.598 NA NA
Laboratory accreditation versus none 1.47 0.118 0.57 0.006 NA NA
Lung ALK EQA scheme 2012–2016, n= 480 (FISH) and n= 363 (IHC)
FISH: Accreditation: yes/no 1.48 0.115 0.58 0.077 0.77 0.368
IHC: Accreditation: yes/no 1.86 0.056 0.88 0.662 0.21 0.009
ALK accreditation (global test) NA NA NA NA 0.034
Gene-speciﬁc versus none NA NA NA NA 0.24 0.118
Laboratory accreditation versus gene-speciﬁc NA NA NA NA 0.81 0.831
Laboratory accreditation versus none NA NA NA NA 0.20 0.018
Lung ROS1 EQA scheme 2014–2015, n= 124 (FISH) and n= 62 (IHC)
FISH: Accreditation: yes/no 0.62 0.192 0.90 0.823 2.37 0.031
IHC: Accreditation: yes/no 1.69 0.417 0.90 0.810 Only 1 failure;
analysis not possible
ROS1 accreditation (global test) NA NA NA NA 0.032
Gene-speciﬁc versus none NA NA NA NA 4.22 0.017
Gene-speciﬁc versus laboratory accreditation NA NA NA NA 1.96 0.268
Laboratory accreditation versus none NA NA NA NA 2.15 0.067
Results are shown for accreditation in general (yes/no) as well as gene-speciﬁc accreditation status in three categories. Global test indicates a difference
between the three accreditation categories: gene-speciﬁc accreditation (KRAS or NRAS), no accreditation and laboratory accreditation (no gene-speciﬁc
accreditation). RAS testing laboratories included those laboratories that tested KRAS and NRAS genes
EQA external quality assessment, IRR Incidence rate ratio, NA not applicable
Accreditation, setting and experience as indicators to assure quality in. . .
V Tack et al.
609
perform as well as accredited laboratories in the long term. The
positive association continues for the EGFR biomarker. The LUNG
EGFR EQA scheme remains a challenging scheme in the long term
because of the use of different types of sample material (cell line
material versus resection specimens), which was not always
included by the laboratories in their initial validation and the large
spectrum of variants.
Nevertheless, in the long term, the effect of accreditation seems
to gain more inﬂuence again, as there is a trend towards less
analysis and technical errors in accredited laboratories for the
routinely used KRAS biomarker. A laboratory with accreditation
must remain attentive and should be able to guarantee a high
quality assurance, even after many years of routine analysis.
The hypothesis that accreditation status of a laboratory has a
positive impact on the correctness of results also has a role in
reporting conclusive results for gene rearrangement and expres-
sion analyses. Accredited laboratories were more careful in
reporting conclusive results for ROS1 FISH analysis, but no
association could be found with ALK FISH. At the time of the
analyses, in 2012, ROS1 was a recently discovered biomarker, not
yet included in any European label for anti-EGFR tyrosine kinase
inhibitors (TKI).33,34 This might be an explanation for the
KRAS
ALK FISH ALK IHC ROS1 FISH ROS1 IHC
Accreditation: EQA score
Accreditation: EQA score
Accreditation: analysis errors
Accreditation: technical
errors
Number of samples : EQA
score
Number of samples : analysis
errors (*EGFR)
Setting: analysis errors
a
b
Setting: EQA score
Setting: analysis errors
Accreditation: technical errors
Accreditation: analysis errors
Setting: EQA score
Number of samples: analysis
errors (*ALK IHC, ROS1 IHC)
Number of samples: EQA score
 (*ALK IHC, ROS1 IHC)
Method: analysis errors
Method: EQA score
RAS EGFR
Fig. 1 Overview of the tested characteristics. The outer line indicates the signiﬁcant results (p < 0.05). The inner line shows the signiﬁcance
level of 0.05. All markers in the centre of the ﬁgure showed no signiﬁcant result. a Variant analysis schemes. b Rearrangement analysis
schemes. *Either the characteristic as a categorical variable or as an ordinal variable gave signiﬁcant results. Analysis errors included false
positive (reported variant/rearrangement/expression in a wild-type sample), false negative (wildtype reported in a tumour containing a
variant/rearrangement/expression) or wrongly reported variants (correct outcome, but wrongly reported variant)
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contradiction.35 Once the ROS1 biomarker becomes a well-known
relevant biomarker, the data should be re-analysed to observe
whether the signiﬁcant effect disappears after few years, similar as
with the variant analysis biomarkers. Accredited laboratories
reported fewer technical errors for ALK IHC, while there was no
association between the percentage of technical failures and
accreditation for ALK FISH rearrangement analysis. This test is for
most laboratories technically more demanding and difﬁcult to
interpret than IHC analysis. Laboratories, independent of their
accreditation status, may introduce this test only after profound
training of their personnel, such that they are able to give valid
and conclusive interpretations. At the time of the analysis, this
analysis could not be repeated for ROS1 IHC, as no data were
available.
Laboratories that work within a setting of university and
research made less analysis errors in variant analysis testing than
laboratories in another setting. It appears that university and
research laboratories have more extensive experience and are
used to innovative methodology, while private and industry
laboratories are more stimulated to work in a cost-effective way. It
is expected that this signiﬁcant result will disappear within a few
years, when new or complex biomarkers are fully integrated into
the routine workﬂow of the laboratories, like what was observed
with the accreditation indicator. There were no signs that these
two indicators were linked to each other, as the university and
research laboratories have an almost equal distribution of
accreditation or no accreditation.
Table 4. Statistical results for the association between the EQA results (EQA score, analysis errors) and the number of samples tested per year
EQA score Analysis errors
Odds ratio p-value IRR p-value
Colon EQA scheme 2010–2016 (all laboratories), n= 688
KRAS categorical (global test) 0.034 0.002
<10 versus more than 10 samples 0.42 0.067 1.68 0.172
10–99 samples versus more than 99 0.41 0.003 2.23 <0.001
100–249 samples versus more than 249 0.69 0.256 1.55 0.038
KRAS ordinal: +1 level 1.47 0.002 0.72 <0.001
Colon EQA scheme 2013–2016 (RAS laboratories), n= 333
NRAS categorical (global test) 0.013 <0.001
<10 versus more than 10 samples 0.44 0.170 1.88 0.2043
10–99 samples versus more than 99 0.22 0.004 3.61 <0.001
100–249 samples versus more than 249 0.51 0.419 1.94 0.0938
NRAS ordinal: +1 level 1.58 0.009 0.64 <0.001
Lung EGFR EQA scheme 2012–2016, n= 457
EGFR categorical (global test) 0.015 0.041
<10 versus more than 10 samples 0.43 0.044 1.88 0.005
10–99 samples versus more than 99 0.74 0.252 1.13 0.543
100–249 samples versus more than 249 0.52 0.010 1.16 0.429
EGFR ordinal: +1 level 1.30 0.009 0.92 0.085
Lung ALK EQA scheme 2012–2016, n= 384 (FISH) and n= 305 (IHC)
ALK FISH categorical (global test) <0.001 0.018
<10 versus more than 10 samples 0.19 <0.001 3.03 0.002
10–99 samples versus more than 99 0.40 0.013 2.18 0.071
100–249 samples versus more than 249 0.61 0.277 1.48 0.529
ALK FISH ordinal: +1 level 1.79 <0.001 0.68 0.005
ALK IHC categorical (global test) 0.022 0.003
<10 versus more than 10 samples 0.39 0.032 2.78 0.009
10–99 samples versus more than 99 0.83 0.647 0.70 0.325
100–249 samples versus more than 249 1.91 0.184 0.80 0.641
ALK IHC ordinal: +1 level 1.19 0.269 0.92 0.595
Lung ROS1 EQA scheme 2014–2015, n= 122 (FISH) and n= 62 (IHC)
ROS1 FISH categorical (global test) 0.865 0.616
ROS1 FISH ordinal: +1 level 1.01 0.937 0.97 0.890
ROS1 IHC categorical (global test) 0.038 0.234
<10 versus more than 10 samples 0.47 0.449 NA NA
10–99 samples versus more than 99 10.47 0.006 NA NA
ROS1 IHC ordinal: +1 level 1.44 0.306 1.36 0.031
For categorical variables, the global test shows the difference between the categories: <10, 10–99, 100–249, 250–499, 500–999, ≥1000. Post hoc comparisons
are only performed when the global p-value is signiﬁcant. RAS testing laboratories included those laboratories that tested KRAS and NRAS genes
EQA external quality assessment, IRR incidence rate ratio, NA not applicable
Accreditation, setting and experience as indicators to assure quality in. . .
V Tack et al.
611
The number of samples analysed per year for RAS and EGFR can
be considered as an inﬂuential indicator for good laboratory
performance. There is no evidence that this indicator was linked to
the previously discussed indicators of accreditation and setting.
RAS-testing of more than 99 samples, compared to 10–99 samples
gave a higher probability of a better EQA score and less analysis
errors. Using these results advocates that centralised biomarker
testing improves quality. Development of a centralised approach
to testing of predictive markers should be promoted soon. Such a
centralised approach will increase the experience of the laboratory
and will be beneﬁcial for the performance of laboratories
performing variant analyses of oncology biomarkers.
There is evidence of an improved EQA FISH performance for a
larger number of samples tested per year for ALK, which is absent
for analysis of ROS1 rearrangements (Table 4). ROS1 was a new
biomarker that was introduced in the laboratory before it became
a mandatory biomarker. In this case, the number of samples tested
per year seems to have no inﬂuence on the EQA results of FISH
analysis. Once the biomarker becomes clinically relevant and
routinely used, enough samples should be tested per year to
KRAS variant analysis
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80%
70%
70%
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Fig. 2 Longitudinal overview of the distribution of techniques in different EQA schemes for (a) (KRAS variant analysis, b NRAS variant analysis
and c EGFR variant analysis. NGS next-generation sequencing, Commercial includes non-NGS-based commercial kits, laboratory includes
developed non-NGS-based laboratory developed
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maintain the high level of experience as every increase in the level
of number of samples tested implies a decrease in analysis errors
of 32% (Table 4). It should be taken into account that less data
were available for ROS1 analysis compared to ALK analysis so this
conclusion should be conﬁrmed in the future.
FISH analysis, including the interpretation, is technically more
difﬁcult compared to a more straightforward IHC analysis. This can
explain why no linear association was found between ALK IHC
analysis and EQA results. Regarding ROS1 IHC analysis, there was
even an increase in false positive and false negative results when
more than 99 ROS1 samples were analysed with IHC per year
compared to 10–99 samples. Also, IHC analysis mainly depends on
antibody sensitivity while FISH analysis requires interpretation by
an experienced operator. It was expected that more experience
with FISH samples is thus needed during the introduction of a new
biomarker. However, this cannot be demonstrated in this study.
The results show an increased use of NGS-based methods and a
decreased use of non-NGS-based LDTs for variant analysis (Fig. 2).
Considering the broader spectrum of relevant biomarkers, this is a
logical evolution in molecular pathology testing. At the time of
introduction of the NRAS biomarker, the availability of non-NGS-
based commercial test kits for NRAS variant analysis was limited.14
There was an extensive use of non-NGS-based LDTs for NRAS
analysis in the Colon EQA scheme of 2013, which was signiﬁcantly
higher than for KRAS variant analysis (p= 0.047). Over the
following years, the ratio changed as more non-NGS-based
commercial NRAS test kits became available. The change in
methods does not seem to inﬂuence the EQA results. Conse-
quently, this characteristic cannot be an indicator of good quality
assurance of biomarker testing.
CONCLUSION
The hypothesis to impose accreditation of laboratories, to
centralise biomarker testing or to test within a setting of university
and research was supported by this study. Results of EQA schemes
in mCRC and NSCLC show that improvement of performance in
oncology biomarker testing is associated with three of the four
tested characteristics. First, laboratory accreditation is needed to
ensure high quality and reliable implementation of new diagnostic
molecular biomarkers. Second, university and research labora-
tories reach more optimal results. Third, larger number of samples
tested per year proved to be an indicator for good EQA results,
implying more centralisation of biomarker testing to reach
sufﬁciently high volumes. Finally, changes in applied methods
do not inﬂuence laboratory performance.
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